Editorial: Positron Emission Tomography (PET) Imaging of Brain Biochemistry: Beyond High-Affinity Radioligands.

We are excited to watch the progress of not only the new radiotracers reported here, but also the many future ones sure to be developed as the improving methods for PET radiochemistry and I in vivo i radiotracer evaluation continue to produce unprecedented radiotracers to be translated to I in vivo i studies in the human brain. PET imaging of misfolded proteins has garnered enormous attention in recent years, yielding radiopharmaceuticals for imaging amyloid and tau in neurodegenerative disorders such as Alzheimer's disease and related dementias. Keywords: brain PET; neuroimaging; radiochemistry; radiopharmaceuticals; molecular imaging EN brain PET neuroimaging radiochemistry radiopharmaceuticals molecular imaging 1 2 2 05/05/22 20220503 NES 220503 The field of radiopharmaceutical chemistry devoted to the development of new neuroimaging agents for Positron Emission Tomography (PET) imaging began in earnest in the early 1980's and was for many years dominated by efforts targeting receptors for the major neurotransmitters such as biogenic amines, amino acids, and acetylcholine. [Extracted from the article]